Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

AbbVie wins CHMP positive opinion to use Skyrizi as an active psoriatic arthritis treatment 

By Brian Buntz | October 15, 2021

AbbVieAbbVie (NYSE:ABBV) announced that the interleukin-23 antagonist Skyrizi (risankizumab) had received backing from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) to treat active psoriatic arthritis.

The committee recommended the drug for adults with active psoriatic arthritis who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs.

CHMP recommended an initial 150-mg of subcutaneous injection of Skyrizi followed by subsequent doses at four weeks and then every 12 weeks after that.

In the U.S., the drug is indicated for certain adults with moderate-to-severe plaque psoriasis. FDA approved the drug in 2019.

In April, North Chicago–based AbbVie announced that it had submitted paperwork to the FDA for the indication of psoriatic arthritis.

Approval for psoriatic arthritis in Europe and the U.S. would elevate AbbVie’s stature in that treatment space, where it already has a strong presence given the popularity of the Humira (adalimumab), which brought in almost $20 billion in revenue last year.

The CHMP positive opinion for Skyrizi was based on data from the KEEPsAKE-1 and KEEPsAKE-2 Phase 3 trials. The drug met the primary and ranked secondary endpoints in both studies.


Filed Under: Rheumatology
Tagged With: AbbVie, CHMP, Committee for Medicinal Products for Human Use, EMA, European Medicines Agency's, psoriatic arthritis., risankizumab, Skyrizi
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Johnson & Johnson Janssen pharmaceutical business in the Pharma 50
Tremfya shows durable efficacy for psoriatic arthritis joint and axial symptoms 
Genascence
Genanscence raises $10.5 million in Series A financing
AbbVie
FDA approves AbbVie’s Rinvoq for active ankylosing spondylitis
GSK
Chinese regulators approve GSK’s Benlysta for lupus nephritis

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50